Action MOC MOLECURE S.A.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Molecure S.A.

Actions

MOC

PLONCTH00011

Temps Différé Warsaw S.E.
Autres places de cotation
 16:01:46 27/06/2024 		Varia. 5j. Varia. 1 janv.
13,74 PLN -0,58 % Graphique intraday de Molecure S.A. -1,43 % -29,54 %
21/05 Molecure S.A. reçoit l'autorisation de lancer un essai clinique de phase II (KITE) pour OATD-01 dans le traitement de la sarcoïdose pulmonaire dans certains pays de l'Union européenne et en Norvège CI
17/05 Molecure S.A. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis
Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
Poland's Molecure Gets US FDA Clearance for Mid-stage Trial of Potential Pulmonary Sarcoidosis Treatment
Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01
Molecure S.A. announced that it has received PLN 49.968 million in funding
Poland's Molecure Files Investigational New Drug Application with US FDA for Pulmonary Sarcoidosis Drug
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023
Molecure S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
Poland's Molecure Doses First Patient in Cancer Treatment Trial
Molecure Announces First Patient Dosed in Phase I Trial with Novel, First-In-Class Dual Arginase Inhibitor OATD-02 for the Treatment of Cancer
Molecure S.A. Announces Management Changes
Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022
Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2022
Molecure S.A.(WSE:MOC) dropped from S&P Global BMI Index
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action MOC
  4. Actualités Molecure S.A.
  5. Autres langues